Companies: 10,795·Total market cap: $144.5T
Design Therapeutics, Inc.

Design Therapeutics, Inc.

DSGNNASDAQHealthcare● Active
$10.46
$-0.19(-1.78%)
Market Cap$653299948
P/E Ratio
52W High$17.25
52W Low$3.33

Design Therapeutics, Inc. (DSGN) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

dsgn · stock forecast · 7 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 7 Wall Street analysts in the past 3 months

SellBuy

Buy

7 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
4
Hold
3
Sell
0
Strong Sell
0
Total: 7 · Buy rate: 57.1%

12-Month Price Target

High

$21.00

Consensus

$20.50

+96.0% upside

Low

$20.00

Median: $20.5 · Last Close: $10.46

The Design Therapeutics, Inc. (DSGN) analyst consensus is Buy, based on ratings from 7 Wall Street analysts over the past 3 months. The average 12-month DSGN price target is $20.50, representing +96.0% upside from the current price of $10.46.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $21 (96.0%)

Consensus Target

$20.50

96.0% upside

High Target

$21

100.8%

Low Target

$20

91.2%

Current Price

$10.46

as of today

Based on analyst price targets, the DSGN stock price prediction for the next 12 months ranges from $20 to $21. The consensus DSGN price forecast of $20.50 implies 96.0% upside from the current price of $10.46.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$9.945.00%

1-day model range: $9.8–$10.08. Peak: $10.08 (-5.00%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$19+80.0%
2028$27+159.3%
2029$34+222.1%
2030$38+265.0%
2031+291.8%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BEARISH

Based on 14 technical indicators

14%7%79%
2Buy
1Neutral
11Sell
RSI (14)46.6Neutral
MACDBEARISH

Refreshes daily from EOD close

Moving Averages · DSGN · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$10.50SELL
MA 10$10.66SELL
MA 20$11.84SELL
MA 50$12.38SELL
MA 100$11.31SELL
MA 200$9.37BUY
Current $DSGN · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$10.56SELL
EMA 10$10.80SELL
EMA 20$11.41SELL
EMA 50$11.80SELL
EMA 100$11.18SELL
EMA 200$9.71BUY
Current $DSGN · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Oppenheimer2026-05-04
Maintains
OutperformOutperform
RBC Capital2026-03-10
Maintains
OutperformOutperform
Leerink Partners2025-12-03
Upgrade ↑
Market PerformOutperform
RBC Capital2025-11-20
Upgrade ↑
Sector PerformOutperform
RBC Capital2025-11-06
Maintains
Sector PerformSector Perform
RBC Capital2024-08-06
Maintains
Sector PerformSector Perform
Piper Sandler2024-05-07
Upgrade ↑
NeutralOverweight
Wedbush2024-03-20
Maintains
NeutralNeutral
RBC Capital2024-03-20
Maintains
Sector PerformSector Perform
RBC Capital2023-11-14
Maintains
Sector PerformSector Perform

Wall Street analysts have recently issued updated ratings on Design Therapeutics, Inc. (DSGN) stock. Of the recent 28 rating actions, 4 were upgrades and 3 were downgrades. 7 analysts currently cover DSGN.

Analyst Recommendation Trends

Buy ratings11
Hold ratings00
Sell ratings00

DSGN analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$117M

↑ 1296.8% YoY

Revenue Next Year

$205M

↑ 74.5% YoY

EPS This Year

$-1.36

EPS Next Year

$-1.64

↑ 20.3% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast DSGN EPS of $-1.36 for the current fiscal year, based on estimates from 5 analysts. The DSGN revenue forecast is $117M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The DSGN stock forecast is supported by two independent data sources: analyst consensus ratings from 7 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus DSGN price target is $20.50 (+96.0% upside), with an analyst consensus of Buy.

The DSGN short-term stock prediction for tomorrow is $9.94 (-5.00%). The DSGN stock price prediction for 2027 estimates an average of $19. The DSGN stock prediction for 2030 projects a range of $32–$44.

Design Therapeutics, Inc. trades on NASDAQ under the ticker DSGN. The DSGN stock outlook for 2027 is broadly positive, supported by a Buy consensus among 57% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

DSGN forecast · 8 questions

According to 7 Wall Street analysts, the average 12-month DSGN price target is $20.50, with a high forecast of $21.00 and a low of $20.00. The median price target is shown in the chart above when available. This implies +96.0% potential upside from the current price of $10.46.

DSGN price targetWhat is DSGN price targetDSGN analyst price targetDSGN 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.